Soligenix (NASDAQ: SNGX) , a late-stage biopharmaceutical company targeting rare diseases, was spotlighted in a July 10 Zacks Small-Cap Research repo ...

One of the more serious side effects from immune checkpoint inhibitor (ICI) therapies for cancer is new-onset or worsened ...

Which of the statements about the use of tumor necrosis factor inhibitors for managing rheumatic disorders are correct?

A new trial finds guselkumab is highly effective and well tolerated for moderate to severe scalp psoriasis in individuals ...

Inverse psoriasis, which causes painful lesions on sensitive skin folds, can be hard to treat. Find out more about this type of psoriasis.

Guselkumab and risankizumab for psoriasis have the highest rates of drug survival among biologics measured and a comparable safety profile.

Incidences of malignant neoplasms were low and stable with long-term ixekizumab treatment for people with psoriatic disease ...

A new preclinical study from scientists at Scripps Research suggests that an existing drug, already approved for treating ...

For patients with psoriasis and Type 2 diabetes, the risk of developing chronic kidney disease (CKD) continued to rise ...

A new analysis highlights the effectiveness of risankizumab in patients with moderate plaque psoriasis and those newly classified as systemic therapy eligible under International Psoriasis Council ...

AD and psoriasis were once thought to be opposites in terms of immune response, with AD linked to a Th2-dominant pathway and ...

There's no sure way to prevent psoriatic arthritis, but managing certain risk factors may reduce the chances of developing it for people with psoriasis.